Fabricio R.
- Country
- Spain
- Department
- Oncology
Research Overview
- Phase 1 Dose-Escalation Study of UGN-301 in Patients with Recurrent Non-Muscle Invasive Bladder Cancer
- Phase I Clinical Trial of TOS-358 in Adult Patients with Advanced Solid Tumors: Colorectal, Cervical, Endometrial, Gastric, Urothelial, Breast, Head and Neck, Ovarian, and NSCLC.
- Evaluation of FS120 Monotherapy and FS120 with Pembrolizumab in Patients with Advanced Malignancies: A First-in-Human Safety and Efficacy Study
Data & Insights
Has run more than one trial at 37 of 108 partner sites.
Specializations
Oncology Research
This investigator specializes in advanced non-small cell lung cancer (NSCLC) and solid tumor therapeutics, focusing on innovative treatment approaches for patients with progressive disease.
- Novel therapeutic agents
- Treatment response evaluation
- Advanced cancer management
The investigator examines therapeutic efficacy through comprehensive assessment of clinical responses and survival outcomes.
Clinical Assessment
Key areas of clinical investigation include monitoring treatment safety profiles and evaluating patient tolerability to various therapeutic combinations.
- Safety assessment protocols
- Drug tolerability studies
- Combination therapy evaluation
Their work encompasses detailed analysis of therapeutic responses and progression patterns in cancer patients.
Treatment Outcomes
The investigator focuses on measuring critical therapeutic endpoints including progression-free survival and objective response rates in oncology patients.
- Response duration assessment
- Survival analysis
- Treatment efficacy evaluation
Their research emphasizes comprehensive evaluation of treatment outcomes in advanced cancer cases.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.